ArticleScientific reports2026
MyoFuse is a fully AI-based workflow for automated quantification of skeletal muscle cell fusion in vitro.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The fusion index (FI) is widely used to assess myoblast differentiation into myotubes, but manual quantification is tedious and biased. Existing automated methods face limitations in nucleus segmentation and classification and often misidentify myoblast nuclei located above or below myotubes, leading to FI overestimation. To address these issues, we developed MyoFuse, an AI-based workflow enabling fully automated and unbiased FI quantification. MyoFuse combines nucleus segmentation using Cellpose with a classification network trained with Svetlana on fluorescence images of mouse C2C12 and human primary myotubes. Performance was evaluated by comparing MyoFuse-derived FI values with expert annotations and by assessing classification accuracy at the single-nucleus level. MyoFuse achieved strong accuracy scores in mouse C2C12 and human primary myotubes (0.954 and 0.911 respectively), and showed strong correlations with expert-derived FI values (r = 0.991 and r = 0.937 respectively; p < 0.0001). Unlike current approaches that overestimate FI, MyoFuse reliably segments nuclei even within dense clusters and distinguishes myotube from myoblast nuclei based solely on cytoplasmic staining. By processing large images, it further reduces selection bias and accounts for heterogeneity in myotube density. MyoFuse thus provides a robust, high-throughput, and accurate method for FI quantification in skeletal muscle cell culture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.